Currentblue cross blue shield - tennesseePolicy N/A

Pancreatic Enzyme Testing for Acute Pancreatitis

Defines coverage criteria for measurement of pancreatic enzymes (serum lipase, amylase, trypsin/trypsinogen/TAP and selected biomarkers) for diagnosis and management of acute and chronic pancreatitis for members of the payer.

Policy Summary

Payerblue cross blue shield - tennessee

PolicyPancreatic Enzyme Testing for Acute Pancreatitis

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionOrder serum lipase (preferred) for individuals with signs/symptoms of acute pancreatitis and avoid routine co-ordering of amylase when lipase is available.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

lipase/amylasemeets coverage criteria for individuals with signs/symptoms of acute pancreatitis

urinary amylasedoes not meet coverage criteria

trypsin/TAP, CRP, ILs, PCTnot covered tests

lipase preferredpreferred test

>3x URLdiagnostic threshold

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

7CPT/HCPCS codes listed

Coverage Criteria

inv-01: Initial diagnostic testing for acute pancreatitis — Covered when ALL of the following are met

Covered when ALL of the following are met

Initial AP enzyme testing: Measurement of either serum lipase (preferred) OR serum amylase for individuals presenting with signs and symptoms of acute pancreatitis (see Note 1).enzyme >= 3x ULN supports diagnosis

Lipase preferred due to greater sensitivity/specificity

inv-02: Tests not meeting coverage criteria for acute pancreatitis — Not covered for diagnosis/assessment/prognosis/severity determination

Not covered for diagnosis/assessment/prognosis/severity determination

Not covered tests for AP: Measurement of serum or urine trypsin/trypsinogen/TAP (trypsinogen activation peptide); C-reactive protein (CRP); interleukin-6 (IL-6); interleukin-8 (IL-8); procalcitonin; and urinary amylase for the initial diagnosis, assessment, prognosis, or determination of severity of acute pancreatitis.

Lack of sufficient published evidence supporting clinical utility

inv-03: Uses of amylase/lipase that do not meet coverage criteria — Not covered uses of otherwise covered tests

Not covered uses of otherwise covered tests

Non-covered indications for serum lipase/amylase: Measurement of serum lipase or amylase as part of ongoing assessment of therapy, to determine prognosis, to determine severity or progression of pancreatitis, more than once per visit, for diagnosis/prognosis/severity of chronic pancreatitis, as part of ongoing assessment/therapy of chronic pancreatitis, or in asymptomatic nonpregnant individuals during general examination without abnormal findings.

These uses do not meet coverage criteria

inv-04: Initial diagnostic criteria — Covered for initial diagnosis when following the Atlanta criteria

Covered for initial diagnosis when following the Atlanta criteria

Initial diagnosis of AP: At least TWO of the following: characteristic abdominal pain; serum amylase or lipase ≥ 3 times the upper limit of normal (URL); radiographic evidence of pancreatitis on cross-sectional imaging.enzyme >3x URL

Either amylase or lipase is acceptable initially, though lipase is preferred per guideline statements and Choosing Wisely

inv-05: Utilization management — Coverage and utilization considerations

Coverage and utilization considerations

Avoid routine co-ordering: Routine concurrent ordering of both amylase and lipase is discouraged because lipase alone provides sufficient diagnostic sensitivity and co-ordering increases costs and may trigger additional downstream testing and consultations.N/A

Studies report cost savings when amylase is removed from order sets; overutilization may prompt review or denial

inv-06: Prognostic/adjunct testing — Adjunctive and prognostic markers — coverage limited or informational

Adjunctive and prognostic markers — coverage limited or informational

Adjunct markers: CRP, procalcitonin, IL-6, IL-8, LDH, ChE, TAP/trypsinogen and urinary trypsinogen-2 may be considered for severity assessment or research contexts but are not supported for routine initial diagnosis; CRP peaks at 48–72 hours and can inform severity (e.g., CRP >150 mg/L at 48 hours in some guidance) but is not for initial diagnostic use.CRP >150 mg/L at 48h suggested in some guidance

Urine trypsinogen-2 dipstick has variable sensitivity/specificity and is not FDA-approved in the US as of 2023

inv-07: Testing preference and limitations — Preferred coverage/clinical criteria inferred from guideline statements

Preferred coverage/clinical criteria inferred from guideline statements

Initial diagnostic testing for suspected acute pancreatitis: Order serum lipase as the preferred initial laboratory test because it has greater sensitivity and a longer diagnostic window compared to amylase.

ASCP/Choosing Wisely, AACC, and NASPGHAN support lipase preference; NASPGHAN cites >=3x ULN as consistent with pancreatitis

When to consider amylase: Consider ordering amylase only when serum lipase testing is not available as a stat test or when specific clinical circumstances warrant (e.g., evaluation of nonpancreatic causes or when rapid amylase normalization is specifically needed).

AACC recommends amylase only if lipase unavailable

Avoid routine dual testing: Do not routinely order both amylase and lipase together because dual testing increases costs with minimal additional diagnostic benefit.

Multiple societies discourage testing both markers

Measurement of urinary amylase, and measurement of serum or urine trypsin/trypsinogen/TAP, as well as biomarkers including C-reactive protein (CRP), interleukin‑6 (IL‑6), interleukin‑8 (IL‑8), and procalcitonin, do not meet coverage criteria for the initial diagnosis, assessment, prognosis, or determination of severity of acute pancreatitis. These tests are excluded from coverage for those indications due to insufficient published evidence supporting their clinical utility in diagnosing or guiding treatment for acute pancreatitis.

A point‑of‑care urine trypsinogen‑2 dipstick test (eg, Actim Pancreatitis) has been developed and reported with variable sensitivity and specificity in published studies, but as of 2023 this dipstick test is not FDA‑approved in the United States. Routine coverage for this assay may be withheld pending regulatory clearance and quality‑control review.

The policy text does not list any additional explicit exclusions beyond the tests specified as not meeting coverage criteria; there are no separate, named policy exclusion statements in the cited sections.

Reference lists and bibliographic sections included in the cited chunks do not identify any explicit coverage exclusions beyond the tests already described in the policy body.

Use of listed biomarkers and pancreatic enzyme tests for prognosis, severity assessment, or ongoing monitoring of acute or chronic pancreatitis is limited. The document specifies that these measurements generally do not meet coverage criteria for prognosis or to determine severity because evidence of clinical utility for these purposes is insufficient.

The policy states that routine repeat measurement of amylase or lipase over time to monitor disease prognosis is of limited value and generally not medically necessary, except when specific clinical indications arise (for example, persistent symptoms or suspected complications).

Routine repeat assessment of pancreatic enzymes for monitoring disease course is discouraged; repeat testing should be reserved for specific clinical changes such as persisting pancreatic or peripancreatic inflammation, suspected ductal obstruction, or development of a pseudocyst, and not used for routine prognosis monitoring.

Within the cited reference list material there are no explicit phrases stating ‘not medically necessary’ beyond the not‑covered and limited‑utility language included elsewhere in the policy body.

Coding and Diagnostic Thresholds

Procedure codes referencedCPT

82150	Amylase
83519	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)
83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified
83529	Interleukin-6 (IL-6)
83690	Lipase
84145	Procalcitonin (PCT)
86140	C-reactive protein

Enzyme elevation threshold — Atlanta classification

ThresholdEnzyme elevation ≥ 3 times the upper limit of normal (Atlanta classification recommendation)

ContextPart of the revised Atlanta diagnostic criteria for acute pancreatitis (two of three criteria required)

PurposeDefines clinically significant amylase or lipase elevation to support diagnosis

Diagnostic enzyme elevation threshold

Threshold>= 3 times the upper limit of the reference range (URL) for serum amylase or lipase

Supporting guidelineIAP/APA 2012 joint guidelines and multiple studies use >=3x URL as diagnostic cutoff

Provider Actions and Operational Guidance

Prior Authorization

Prior Authorization for Co-ordering

Prior authorization for co-ordering of serum amylase when serum lipase is available: Studies show consistent cost savings and reduced unnecessary testing when amylase is eliminated from routine order sets and lipase is ordered alone. Payers may therefore consider prior authorization or utilization management strategies to discourage co-ordering of amylase with lipase when lipase is available and clinically appropriate.

Consider prior authorization or edits to deny routine co-ordering of amylase + lipase when lipase is available.
Allow amylase only when lipase is unavailable or when clinical justification is documented (see Documentation guidance).

Billing Rule

Procedure Code Reference

Procedure code references provided for operational and claims processing. These codes are included for reference and may not be all-inclusive.

Background

Acute pancreatitis is inflammation of the pancreas diagnosed when at least two of three criteria are present: characteristic abdominal pain; a serum lipase or amylase ≥ 3× the upper limit of normal; or characteristic findings on contrast‑enhanced CT (or MRI/ultrasound). Serum lipase is the preferred initial laboratory test due to greater sensitivity and a longer diagnostic window compared with amylase.

Definitions

Acute pancreatitis diagnostic criteria

Diagnostic ruleDiagnosis of acute pancreatitis requires at least TWO of: characteristic abdominal pain; serum amylase or lipase ≥3× ULN; characteristic imaging findings (CECT/MRI/ultrasound)

Pain descriptionAcute onset of persistent, severe epigastric pain often radiating to the back

Imaging roleContrast-enhanced CT is used for radiographic confirmation; MRI/ultrasound less commonly

Amylase — characteristics and timing

SourceAmylase is produced predominantly in salivary glands and pancreas (s- and p-isoforms)

KineticsAmylase rises after pancreatic injury but returns to normal sooner; half-life ~12 hours (renal excretion)

Policy Summary

Payerblue cross blue shield - tennessee

PolicyPancreatic Enzyme Testing for Acute Pancreatitis

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionOrder serum lipase (preferred) for individuals with signs/symptoms of acute pancreatitis and avoid routine co-ordering of amylase when lipase is available.

SourceLink

On This Page

NoteSome studies used lower thresholds (eg, 2x URL), but Atlanta and guideline statements recommend >=3x URL

Diagnostic enzyme threshold — serum lipase or amylase

ThresholdSerum lipase or amylase ≥ 3 times upper limit of normal is consistent with acute pancreatitis

Preferred analyteLipase is preferred over amylase due to greater sensitivity and specificity

TimingBoth enzymes rise within hours of symptom onset; lipase remains elevated longer (1–2 weeks)

82150 — Amylase
83690 — Lipase
83519, 83520 — Immunoassay (quantitative)
83529 — Interleukin-6 (IL-6)
84145 — Procalcitonin (PCT)
86140 — C-reactive protein (CRP)

Prior Authorization

Prior authorization: No routine prior authorization requirement for ordering lipase for individuals presenting with signs/symptoms of acute pancreatitis. However, prior authorization or utilization management may be applied to co-ordering or repeat testing that is inconsistent with coverage criteria.

Lipase (or amylase if lipase unavailable) for initial diagnosis when signs/symptoms of acute pancreatitis are present: no prior auth required.
Prior authorization or claim edits may be applied to: routine co-ordering of amylase + lipase; repeat enzyme testing more than once per visit; tests ordered for indications listed as not meeting coverage (see coverage criteria).

Documentation Required

Clinical Documentation to Support Covered Testing

Clinical documentation to support covered testing: Document signs and symptoms consistent with acute pancreatitis and clinical rationale for the test ordered. Coverage for initial enzyme testing requires presentation with symptoms suggestive of acute pancreatitis.

Document acute abdominal pain characteristics, nausea/vomiting, fever, hypotension, tachypnea, hypoxemia, abdominal tenderness/distension, or other listed signs.
Indicate whether testing is for initial diagnosis versus monitoring — initial diagnostic testing is covered when symptomatic; routine monitoring or prognosis assessment is not covered.

Documentation Required

Documentation Guidance

Documentation guidance when ordering amylase: If ordering amylase (instead of or in addition to lipase), explicitly document why lipase is unavailable or why amylase is clinically necessary (e.g., lipase stat not available and urgent decision needed). When amylase is ordered despite availability of lipase, include rationale in the medical record to support medical necessity.

Document the unavailability of lipase as a stat test if that is the reason for amylase ordering.
When co-ordering is clinically justified (rare), document specific clinical circumstances supporting the combined order.

Note

No Specific Documentation Forms Required

No documentation requirements specified in the reference list: The source reference chunks do not prescribe specific forms or templates for documentation beyond standard clinical documentation of signs/symptoms and rationale.

Follow standard medical record documentation practices; no additional proprietary documentation forms are mandated by these references.

Note

Preferred Test Ordering

Preferred test ordering: Serum lipase is preferred over amylase for initial diagnosis of acute pancreatitis. Routine co-ordering of both tests is discouraged because it increases costs with minimal improvement in diagnostic yield.

Order serum lipase as the first-line enzyme test for suspected acute pancreatitis.
Avoid routine simultaneous ordering of serum amylase when lipase is available.

Note

Prefer Lipase Before Amylase

Prefer lipase before amylase: Guidelines and expert recommendations consistently favor lipase alone for initial diagnosis; amylase may be considered only when lipase testing is not available.

If both tests are available, order lipase and do not order amylase routinely.
Amylase may be ordered only if lipase is unavailable or specific clinical circumstances require it, with documentation of rationale.

Note

Preferred First-line Test

Preferred first-line test operational rule: When serum lipase testing is available, do not order amylase as a first-line test. Use amylase only as an alternative when lipase is inaccessible or when there is an explicit, documented clinical justification.

First-line: Serum lipase for individuals with signs/symptoms of acute pancreatitis.
First-line amylase acceptable only if lipase testing is unavailable as a stat test and documented justification exists.

LimitationsAmylase may be normal in hypertriglyceridemia- or alcohol-associated AP and can be elevated in nonpancreatic conditions

Lipase — characteristics and preference

SourceLipase is a pancreatic enzyme with higher sensitivity and specificity than amylase

KineticsRises within 3–6 hours and remains elevated for 1–2 weeks, providing a wider diagnostic window

GuidanceSocieties and Choosing Wisely recommend lipase over amylase for initial testing

Diagnostic threshold — guideline recommendation

RecommendationAtlanta classification and multiple professional societies recommend a diagnostic threshold of ≥3× the upper limit of normal (URL) for amylase or lipase

Clinical useThreshold used to define clinically significant enzyme elevation supporting diagnosis

Guideline concordanceNASPGHAN, IAP/APA, ACG, and AGA reference the ≥3× URL threshold

Trypsin / TAP / trypsinogen-2 — biomarker description

Biomarker descriptionTrypsin is activated from trypsinogen; TAP (trypsinogen activation peptide) and trypsin are released during pancreatic injury

Clinical roleMarkers have been investigated for diagnosis and severity assessment due to early release during injury

LimitationsEvidence on TAP/trypsinogen utility is mixed and not universally adopted for routine diagnosis

Diagnostic threshold — NASPGHAN

NASPGHAN thresholdNASPGHAN considers a serum lipase or amylase level of at least 3 times the upper limit of normal as consistent with pancreatitis

ScopeStatement applies to pediatric population but aligns with adult guideline thresholds

ValidationNASPGHAN notes other biomarkers have been investigated but many are not validated for general clinical use

Urinary trypsinogen / TAP — evaluation and context

Evaluated markersUrinary trypsinogen and trypsinogen activation peptide (TAP) have been studied as diagnostic and severity biomarkers

POC testingA urine trypsinogen-2 dipstick exists with variable reported sensitivity/specificity; not FDA-approved in the U.S. as of 2023

EvidenceStudies report mixed performance; some show high specificity/sensitivity while others find limited value for diagnosis/severity

Serum amylase and lipase — standard enzymes and evidence

Standard enzymesSerum amylase and lipase are the standard laboratory enzymes used to diagnose acute pancreatitis

Comparative literatureMultiple studies and systematic reviews compare diagnostic accuracy; overall lipase demonstrates higher sensitivity and specificity

Clinical implicationGuidelines generally recommend using lipase rather than routine dual testing with amylase